Page last updated: 2024-08-23

idazoxan and Parkinson Disease, Secondary

idazoxan has been researched along with Parkinson Disease, Secondary in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Connor, TJ; Harkin, A; Nolan, YM; O'Neill, E; Yssel, JD	1
Colpaert, F; Domino, EF; Marien, M; Ni, L	1

Other Studies

2 other study(ies) available for idazoxan and Parkinson Disease, Secondary

Article	Year
Treatment with the noradrenaline re-uptake inhibitor atomoxetine alone and in combination with the α2-adrenoceptor antagonist idazoxan attenuates loss of dopamine and associated motor deficits in the LPS inflammatory rat model of Parkinson's disease. Brain, behavior, and immunity, 2018, Volume: 69 Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Brain; Dopamine; Dopaminergic Neurons; Idazoxan; Lipopolysaccharides; Motor Activity; Neuroprotective Agents; Parkinson Disease, Secondary; Rats; Rats, Wistar; Treatment Outcome	2018
Effects of (+/-)-idazoxan alone and in combination with L-DOPA methyl ester in MPTP-induced hemiparkinsonian monkeys. Receptors & channels, 2003, Volume: 9, Issue:5 Topics: Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Idazoxan; Levodopa; Macaca nemestrina; Parkinson Disease, Secondary; Time Factors	2003

Article

Year

Treatment with the noradrenaline re-uptake inhibitor atomoxetine alone and in combination with the α2-adrenoceptor antagonist idazoxan attenuates loss of dopamine and associated motor deficits in the LPS inflammatory rat model of Parkinson's disease.

Brain, behavior, and immunity, 2018, Volume: 69

Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Brain; Dopamine; Dopaminergic Neurons; Idazoxan; Lipopolysaccharides; Motor Activity; Neuroprotective Agents; Parkinson Disease, Secondary; Rats; Rats, Wistar; Treatment Outcome

2018

Effects of (+/-)-idazoxan alone and in combination with L-DOPA methyl ester in MPTP-induced hemiparkinsonian monkeys.

Receptors & channels, 2003, Volume: 9, Issue:5

Topics: Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Idazoxan; Levodopa; Macaca nemestrina; Parkinson Disease, Secondary; Time Factors

2003